

IN THE CLAIMS:

Please cancel 29, 31, and 33-35, amend claims 26-28, 30 and 32, and add new claims 36-40 as set forth in the complete claim listing below. This listing of claims will replace all prior versions and listings of claims in the application:

1-25 (Cancelled).

26.(Currently Amended) A method of treating a tumor in a subject, said tumor comprising malignant cancer cells having an operative retinoblastoma (RB) protein, by dephosphorylizing the RB protein in said cancer cells and continuously maintaining a dephosphorylated state of the RB in said cancer cells to induce apoptosis thereof, comprising the steps of:

administering to a subject a pharmaceutically effective dosage of an ~~agent drug~~ to cause an increase in E/ decrease in the  $[GSH]^2/[GSSG]$  (wherein [GSH] is the concentration of glutathione and [GSSG] is the concentration of glutathione disulfide) ratio in the malignant cancer cells of said tumor, said ~~agent drug~~ comprising ~~any one or~~ a combination of at least one E-increasing agent from the group of disulfiram[,] and curcumin, and at least one enzyme deactivating agent from the group of BCNU and BSO;

said pharmaceutically effective dosage of said ~~agent drug~~ being calibrated further comprising a calibrated administration frequency to continuously maintain said decreased  $[GSH]^2/[GSSG]$  ratio in the malignant cells and consequently continuously maintain said dephosphorylated state of the RB in said cancer cells within a range of from 15 to 75 hours in order to span at least one cell cycle.

27. (Currently Amended). A method in accordance with claim 26, wherein said ~~agent drug~~ comprises an in vivo synergistic combination of at least two from among the group of disulfiram, curcumin[,] and BCNU and BSO.

28. (Currently Amended). A method in accordance with claim 26, wherein said ~~agent drug includes disulfram~~ comprises an in vivo synergistic combination of curcumin and BSO.

29. (Canceled).

30. (Currently Amended). A method in accordance with claim 26, wherein said ~~drug~~ comprises an in vivo synergistic combination of disulfram and BCNU ~~agent includes curcumin.~~

31. (Canceled).

32. (Currently Amended). A method in accordance with claim 26, wherein said drug comprises an in vivo synergistic combination of disulfram and BSO ~~agent includes BCNU.~~

33. (Canceled).

34. (Canceled).

35. (Canceled).

36.(New) A method of treating a tumor in a subject, said tumor comprising malignant cancer cells having an operative retinoblastoma (RB) protein, by dephosphorylizing the RB protein in said cancer cells and continuously maintaining a dephosphorylated state of the RB in said cancer cells to induce apoptosis thereof, comprising the steps of:

administering to a subject a pharmaceutically effective dosage of a drug to cause an increase in E/ decrease in the  $[GSH]^2/[GSSG]$  (wherein  $[GSH]$  is the concentration of glutathione and  $[GSSG]$  is the concentration of glutathione disulfide) ratio in the malignant cancer cells of said tumor, said drug

comprising a combination of two E-increasing agents and two enzyme deactivating agents;

said pharmaceutically effective dosage of said drug further comprising a calibrated administration frequency to continuously maintain said decreased  $[GSH]^2/[GSSG]$  ratio in the malignant cells and consequently continuously maintain said dephosphorylated state of the RB in said cancer cells within a range of from 15 to 75 hours in order to span at least one cell cycle.

37. (New). A method in accordance with claim 36, wherein said two E-increasing agents comprise disulfram and curcumin.

38. (New). A method in accordance with claim 36, wherein said two enzyme deactivating agents comprise BCNU and BSO.

39. (New). A method in accordance with claim 37, wherein said two enzyme deactivating agents comprise BCNU and BSO.

40. (New). A method in accordance with claim 36, wherein said two E-increasing agents consist of disulfram and curcumin, and said two enzyme deactivating agents consist of BCNU and BSO.